Evidence map›Paper›PMID 32373113›Full record

ArticleFrontiers in immunology2020

Missing-in-Metastasis/Metastasis Suppressor 1 Regulates B Cell Receptor Signaling, B Cell Metabolic Potential, and T Cell-Independent Immune Responses.

Alexey V Sarapulov, Petar Petrov, Sara Hernández-Pérez, Vid Šuštar, Elina Kuokkanen, Lena Cords, Rufus V M Samuel, Marika Vainio, Marco Fritzsche, Yolanda R Carrasco and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. MTSS1: beyond the integration of actin and membrane dynamics.Cellular and molecular life sciences : CMLS · 2024
    Review
  6. Article
  7. B cells in tumor metastasis: friend or foe?International journal of biological sciences · 2023
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Alexey V SarapulovInstitute of Biomedicine and MediCity Research Laboratories, University of Turku, Turku, Finland.
Petar PetrovInstitute of Biomedicine and MediCity Research Laboratories, University of Turku, Turku, Finland.
Sara Hernández-PérezInstitute of Biomedicine and MediCity Research Laboratories, University of Turku, Turku, Finland.
Vid ŠuštarInstitute of Biomedicine and MediCity Research Laboratories, University of Turku, Turku, Finland.
Elina KuokkanenInstitute of Biomedicine and MediCity Research Laboratories, University of Turku, Turku, Finland.
Lena CordsMRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Rufus V M SamuelInstitute of Biomedicine and MediCity Research Laboratories, University of Turku, Turku, Finland.
Marika VainioInstitute of Biomedicine and MediCity Research Laboratories, University of Turku, Turku, Finland.
Marco FritzscheKennedy Institute for Rheumatology, University of Oxford, Oxford, United Kingdom.
Yolanda R CarrascoDepartment of Immunology and Oncology, Centro Nacional de Biotecnología (CNB)-CSIC, Madrid, Spain.
Pieta K MattilaInstitute of Biomedicine and MediCity Research Laboratories, University of Turku, Turku, Finland.
University of Turku · FIÅbo Akademi University · FICentro Nacional de Biotecnología · ESMRC Human Immunology Unit · GBRosalind Franklin Institute · GB

Funding

Wellcome TrustWellcome Trust 212343/Z/18/Z
6 · The paper itself

Abstract

Efficient generation of antibodies by B cells is one of the prerequisites of protective immunity. B cell activation by cognate antigens via B cell receptors (BCRs), or pathogen-associated molecules through pattern-recognition receptors, such as Toll-like receptors (TLRs), leads to transcriptional and metabolic changes that ultimately transform B cells into antibody-producing plasma cells or memory cells. BCR signaling and a number of steps downstream of it rely on coordinated action of cellular membranes and the actin cytoskeleton, tightly controlled by concerted action of multiple regulatory proteins, some of them exclusive to B cells. Here, we dissect the role of Missing-In-Metastasis (MIM), or Metastasis suppressor 1 (MTSS1), a cancer-associated membrane and actin cytoskeleton regulating protein, in B cell-mediated immunity by taking advantage of MIM knockout mouse strain. We show undisturbed B cell development and largely normal composition of B cell compartments in the periphery. Interestingly, we found that MIM

Indexed as

AnimalsAntibody FormationB-LymphocytesFemaleImmunological SynapsesLipopolysaccharidesLymphocyte ActivationMiceMice, Inbred C57BLMicrofilament ProteinsNeoplasm ProteinsOligodeoxyribonucleotidesReceptors, Antigen, B-CellSignal TransductionT-LymphocytesToll-Like ReceptorsCPG-oligonucleotideLipopolysaccharidesMicrofilament ProteinsMtss1 protein, mouseNeoplasm ProteinsOligodeoxyribonucleotidesReceptors, Antigen, B-CellToll-Like Receptorsactin cytoskeletonB cell receptor signalingBCRI-BAR domain proteinmetabolismMIMMTSS1TLR

Identifiers

PMID32373113
PMCPMC7176992
OpenAlexW3016413603

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.